Axsome Therapeutics (NASDAQ:AXSM) Director Sells $4,027,750.00 in Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Mark Coleman sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $161.11, for a total value of $4,027,750.00. Following the completion of the sale, the director directly owned 47,140 shares of the company’s stock, valued at approximately $7,594,725.40. The trade was a 34.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Axsome Therapeutics Stock Up 0.4%

AXSM stock opened at $163.89 on Monday. The company has a current ratio of 1.55, a quick ratio of 1.48 and a debt-to-equity ratio of 1.38. The firm has a market capitalization of $8.38 billion, a PE ratio of -44.41 and a beta of 0.43. Axsome Therapeutics, Inc. has a 1-year low of $86.99 and a 1-year high of $191.50. The business’s 50 day simple moving average is $175.78 and its 200 day simple moving average is $146.61.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.14. Axsome Therapeutics had a negative return on equity of 232.61% and a negative net margin of 28.69%.The business had revenue of $196.00 million during the quarter, compared to the consensus estimate of $191.33 million. The company’s quarterly revenue was up 65.0% compared to the same quarter last year. As a group, research analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Key Headlines Impacting Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $260 price target and forecasts a large rebound into FY‑2027 (FY‑2027 EPS of $11.87 with strong quarterly ramps). This upbeat long‑term view supports investor optimism. Read More.
• Positive Sentiment: Recent company results showed a Q4 EPS beat and revenue up ~65% year‑over‑year, which provides fundamental support for the stock despite near‑term model revisions. Read More.
• Neutral Sentiment: Reported short interest data in late February shows effectively zero shares short (the published figures contain anomalies/NaN), so short‑position dynamics appear minimal and unlikely to be a near‑term driver. Read More.
• Negative Sentiment: HC Wainwright trimmed multiple near‑term 2026 estimates (Q1‑Q3 and FY‑2026 materially lowered; Q4‑2026 also revised down from prior forecasts). These cuts signal more modest near‑term profitability than previously expected and increase uncertainty for 2026 results. Read More.

Hedge Funds Weigh In On Axsome Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in shares of Axsome Therapeutics by 6.0% during the 3rd quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock valued at $507,739,000 after acquiring an additional 235,626 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Axsome Therapeutics by 45.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,509,870 shares of the company’s stock valued at $275,763,000 after purchasing an additional 472,422 shares in the last quarter. Wellington Management Group LLP raised its stake in Axsome Therapeutics by 84.1% in the third quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock valued at $162,082,000 after purchasing an additional 609,516 shares in the last quarter. Invesco Ltd. lifted its position in Axsome Therapeutics by 28.6% during the fourth quarter. Invesco Ltd. now owns 1,273,494 shares of the company’s stock worth $232,591,000 after purchasing an additional 282,937 shares during the period. Finally, Geode Capital Management LLC grew its stake in Axsome Therapeutics by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 1,010,249 shares of the company’s stock worth $184,544,000 after buying an additional 12,549 shares in the last quarter. Institutional investors own 81.49% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Robert W. Baird set a $209.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday, January 13th. UBS Group increased their target price on Axsome Therapeutics from $248.00 to $251.00 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. Piper Sandler boosted their price target on Axsome Therapeutics from $148.00 to $223.00 and gave the company an “overweight” rating in a research note on Friday, January 16th. Leerink Partners upped their price objective on Axsome Therapeutics from $150.00 to $205.00 and gave the company an “outperform” rating in a report on Wednesday, January 28th. Finally, Wells Fargo & Company lifted their target price on Axsome Therapeutics from $193.00 to $202.00 and gave the stock an “overweight” rating in a report on Tuesday, February 24th. Seventeen analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Axsome Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $216.12.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.